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ABSTRACT
Prostate cancer at advanced stages including metastatic and castrationresistant cancer remains incurable due to the lack of effective therapies. The
CAMK2N1 gene, cloned and characterized as an inhibitor of CaMKII (calcium/
calmodulin-dependent protein kinase II), has been shown to affect tumorigenesis
and tumor growth. However, it is still unknown whether CAMK2N1 plays a role in
prostate cancer development. We first examined the protein and mRNA levels of
CAMK2N1 and observed a significant decrease in human prostate cancers comparing
to normal prostate tissues. Re-expression of CAMK2N1 in prostate cancer cells
reduced cellular proliferation, arrested cells in G0/G1 phases, and induced apoptotic
cell death accompanied by down-regulation of IGF-1, ErbB2, and VEGF downstream
kinases PI3K/AKT, as well as the MEK/ERK-mediated signaling pathways. Conversely,
knockdown of CAMK2N1 had a significant opposite effects on these phenotypes.
Our analyses suggest that CAMK2N1 plays a tumor suppressive role in prostate
cancer cells. Reduced CAMK2N1 expression correlates to human prostate cancer
progression and predicts poor clinical outcome, indicating that CAMK2N1 may serve
as a biomarker. The inhibition of tumor growth by expressing CAMK2N1 established
a role of CAMK2N1 as a therapeutic target.

INTRODUCTION

sensitive to -resistant, inevitably developing highly
metastatic properties [2]. Prostate tumors initially
respond to hormonal intervention therapies, however,
with androgen-independence emerging, tumors develop
resistance to anti-androgen therapies [3]. The frontline
treatments for advanced prostate cancer consist

Prostate cancer is one of the most common
malignancies among men and the second most common
cause of male cancer-related deaths [1]. The usual
progression of prostate cancer goes from castrationwww.impactjournals.com/oncotarget
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of hormone therapy, chemotherapy, and radiation.
Unfortunately, limited therapy options are stalling the
survival rates in patients [4, 5].
CAMK2N1
(calcium/calmodulin-dependent
protein kinase II inhibitor 1, also known as PRO1489),
a peptide composed of 78-amino acids, was initially
shown to localize in the cell junction and synapse [6,
7, 8]. CAMK2N1 functions as a potent and specific
inhibitor of CaMKII (calcium/calmodulin-dependent
protein kinase II). CaMKII is a member of the Calcium/
calmodulin (CaM) 2-dependent protein kinase family,
and is a ubiquitous serine/threonine protein kinase that
phosphorylates nearly 40 different proteins, including
enzymes, ion channels, kinases and transcription factors
[7, 8]. CaMKII signaling plays a role in cell-cycle
progression by activating MEK/ERK to enhance the
phosphorylation of p27Kip1[8]. Inhibition of CaMKII
activity by synthetic agents has been shown to suppress
cell growth [9]. In addition, CAMK2N1-mediated
inhibition of CaMKII activity regulates the cell-cycle
progression in colon cancer cells through de-activation of
MEK/ERK kinase activity and p27 protein accumulation
[7, 8]. Currently, it is still unknown whether CAMK2N1
plays any role in prostate cancer development.
In this study, we performed immunohistochemical
(IHC) staining using human prostate cancer specimens
and observed a significant reduction of CAMK2N1 in
prostate cancer compared to normal tissue. Decreased
CAMK2N1 expression correlated with more advanced
stages of prostate cancer. We observed that overexpression
of CAMK2N1 significantly impaired human prostate
cancer cell proliferation and tumor growth in vivo, while
depletion of CAMK2N1 promoted cell proliferation and
tumor growth. Genome-wide gene profiling revealed
that CAMK2N1 regulated the expression of key proteins
associated with cell-cycle progression and apoptosis.
Taken together, our findings revealed a tumor suppressive
role for CAMK2N1 and established CAMK2N1 as
molecular determinant in hormone sensitivity of prostate
cancer.

cancerous tissues with moderate expression in early stages
(I/II) and poor expression in advanced stages (III/IV). The
nuclear CAMK2N1 staining was quantified in human
prostate tumors (n = 50), hyperplastic tissues (n = 20), and
normal control specimens (n = 10) (Fig. 1B). Next, we
analyzed the abundance of CAMK2N1 mRNA in prostate
cancer tissues compared to matched normal-like control
from same patient (n = 10) by quantitative RT-PCR (qRTPCR) analysis. As shown in Fig. 1C, the mRNA level of
CAMK2N1 was significantly reduced in prostate cancer
tissues compared to normal prostate, which is consistent
with the reduced protein expression in prostate cancer
cells.
Next, we examined CAMK2N1 mRNA levels
by qRT-PCR in several most commonly used prostate
epithelial cells, including AR-negative PC3 and DU145
cells, AR-positive castration-sensitive LNCaP cell and
RWPE1, a normal prostate cell line serving as control.
As shown in Fig. 1D, all prostate cancer cells exhibited
decreased expression of CAMK2N1, with LNCaP being
closest to the control. Taken together, these observations
suggest that the level of CAMK2N1 is reduced in both
human prostate cancer patient samples and commonly
used prostate cancer cells.

CAMK2N1 inhibits prostate cancer
proliferation and cell cycle progression

To determine the functional significance of
CAMK2N1 in regulating human prostate cancer growth,
we first analyzed whether CAMK2N1 regulates the
proliferation of human prostate cancer cells by MTT
assays. We found that overexpression of CAMK2N1 in
DU145 and PC3 cells inhibited cellular proliferation (Fig.
2A-B), and conversely, depletion of CAMK2N1 in DU145
cells using shRNAs targeting CAMPK2N1 enhanced cell
proliferation (Fig. 2C). To further analyze the effect of
CAMK2N1 on cell-cycle progression, FACS analysis was
conducted. Overexpression of CAMK2N1 increased G0/G1
cell fraction and reduced the proportion of cells in S-phase
after 24 hrs post serum induction in serum-starved DU145
and PC3 cells (Fig. 2D-E, Supplemental Fig. 2A), while
knockdown of CAMK2N1 in DU145 cells with shRNA
reduced the proportion of cells in G0/G1 and increased the
proportion of cells in S-phase (Supplemental Fig. 1A).
To further determine whether CAMK2N1
inhibits oncogenic growth of prostate cancer cells, we
performed colony formation assays. Ectopic expression
of CAMK2N1 inhibited both the number and the size of
colonies by 30% - 40% (Fig. 2F-K,), while the shRNAmediated knockdown of CAMK2N1 enhanced DU145
colony formation (Supplemental Fig. 1B).

RESULTS
Reduced CAMK2N1 expression in human
prostate cancer
We first analyzed CAMK2N1 protein expression
in human prostate cancer specimens by performing
immunohistochemical (IHC) staining. In normal prostate
tissue, CAMK2N1 showed whole cell distribution with
stronger staining in the nucleus compared to cytoplasm
(Fig. 1A). Hyperplastic and normal tissues had similar
expression levels and distribution patterns (Fig 1A-B).
However, CAMK2N1 protein levels were decreased in
www.impactjournals.com/oncotarget
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Figure 1: CAMK2N1 abundance is reduced in human prostate cancer. (A) Representative examples of immunohistochemical
staining for CAMK2N1 in each of the clinical stages of prostate cancers as indicated. (B) Quantification of CAMK2N1 relative
immunostaining intensity for each clinical stage of prostate cancers. Data is shown as mean ± SEM for N as indicated in the figure in
parethesis as shown. (C) CAMK2N1 mRNA determined by quantitative PCR. Comparison was made between normal and tumorous
prostate samples. (D) QT-PCR analysis of CAMK2N1 expression in prostate cell lines (RWPE1, LNCaP, DU145, PC3).
www.impactjournals.com/oncotarget
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CAMK2N1 inhibits prostate tumor growth in vivo

the expression of CAMK2N1 (Fig. 3D, E, I, J). These
observations suggest that CAMK2N1 negatively regulate
prostate tumor growth in vivo.

Encouraged by these observations, we then
investigated the role of CAMK2N1 in inhibiting
prostate tumor growth in vivo. DU145 and PC3 cells
stably transduced with an expression vector encoding
CAMK2N1 were implanted subcutaneously into immunedeficient mice. Tumor size was measured every 5 days
with last measuring performed on day 32 (Fig. 3A, F).
We observed that that overexpression of CAMK2N1
significantly reduced both the tumor size (Fig. 3B,G) and
the tumor weight (Fig. 3C, H). IHC staining demonstrated

CAMK2N1 induces apoptotic cell death in human
prostate cancer cells.
Since elevated cell death may also contribute
to impaired tumor growth, we determined whether
CAMK2N1 induces apoptosis by Annexin V staining
and TUNEL assays. Annexin V staining revealed that
proportion of cells in early and late apoptosis was

Figure 2: CAMK2N1 inhibits prostate cancer cell proliferation and cell cycle progression. DU145 and PC3 cells stably
overexpressed or knocked down CAMK2N1. Cells were analyzed for cell proliferation by (A-C) MTT, cell cycle by (D-E) FACS and
oncogenic growth by (F-K) Colony-forming assay. Data is shown as mean ± SEM for N > 5 separate experiments.
www.impactjournals.com/oncotarget
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Figure 3: CAMK2N1 inhibits prostate tumor growth in vivo. (A-J) Serial measurements were conducted every five days of

DU145 and PC3 tumors stably expressing CAMK2N1, injected into nude mice. The data is shown as mean ± SEM for N>6 separate tumors
for each group. (A, F) Images of tumors dissected out from the sacrificed mice. (B, G) The tumor size (mm3) versus days of post injection.
(C, H) Reduction in tumor weight after resection at the end of experiment. (D-E, I-J) IHC staining detected the expression of CAMK2N1
in DU145 and PC3 tumor tissues of nude mice.
www.impactjournals.com/oncotarget
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increased in CAMK2N1 overexpressing DU145 cells
(Fig. 4A) and PC3 cells (Supplemental Figure 2B).
TUNEL staining was conducted to assess the effect of
CAMK2N1 on cell apoptosis in tumor samples from in
vivo experiment. Similarly, the percentage of apoptotic
cells was increased in CAMK2N1 overexpressing tumor

derived from nude mice implanted with DU145 cells (Fig.
4B). To determine the expression of Bax, Bcl-2, p21,
and Ki67 in tumor tissues, we conducted IHC staining
in tumors with over-expressed CAM2KN1. As shown in
Fig. 4C, tumors overexpressing CAM2KN1 have reduced
expression of Bcl-2, Ki67 and increased p21 and Bax

Figure 4: CAMK2N1 induces apoptotic cell death in human prostate cancer cells. DU145 cells stably overexpressed

CAMK2N1. These cells were analyzed for apoptosis by (A) Annexin V staining. Quantification of colony numbers and sizes were shown
as mean ± SEM for N>5 separate experiments. (B) TUNEL staining was conducted to assess the effect of CAMK2N1 on cellular apoptosis
in vivo. The percentage of apoptotic cells was increased in DU145 tumor tissues derived from nude mice. Quantification of TUNEL staining
was shown as mean ± SEM for N=4 separate experiments. (C) IHC staining detected the expression of Bax, Bcl2, p21 and Ki67 in DU145
tumor tissue of nude mice. Overexpression of CAM2KN1 in DU145 and PC3 tumor tissue decreased Bcl-2, Ki67 protein expression and
increased p21, Bax protein expression. Data for quantified IHC was shown as mean ± SEM for N = 4 tumors in each group.
www.impactjournals.com/oncotarget
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DISSCUSSION

expression, suggesting that gain of CAM2KN1 promotes
apoptosis in prostate cancer cells.

In this study, we demonstrated that CAMK2N1
plays a tumor suppressive role in human prostate
cancer. CAMK2N1 is significantly reduced in prostate
cancer compared to benign and normal prostate tissues.
Reduced CAMK2N1 expression positively correlated
with prostate tumor progression (stage, TNM). Consistent
with the expression pattern in normal and malignant
prostate tissues, CAMK2N1 was expressed at a higher
level in non-tumorigenic prostate epithelial cells. In
addition, a moderate expression of CAMK2N1 was
detected in castration sensitive LNCaP cells, while its
expression was relatively low in castration-resistant
prostate cancer DU145 and PC3 cells. Overexpression
of CAMK2N1 in DU145 and PC3 cells led to the
inhibition of cell proliferation, accumulation in G0/G1
phase and the induction of apoptosis, while CAMK2N1
knockdown promoted S-phase entry after release from
G0/G1 synchronization and enhanced cell proliferation in
DU145 cells.
CAMK2N1 is the specific inhibitor of CaMKII.
As a ubiquitous serine/threonine protein kinase, CaMKII
phosphorylates nearly forty different proteins, including
enzymes, ion channels, kinases and transcription factors
[7, 8]. In previous studies, CAMKII was involved
in insulin-induced cell proliferation [10]. CaMKII
phosphorylates Raf-1 at S338 and participates in ERK
activation upon different stimuli [11]. Furthermore,
CAMK2N1-mediated inhibition of CAMKII activity
caused deactivation of MEK/ERK kinase activity and
accumulation of p27 protein, which primarily regulates
the cell cycle progression of colon cancer cells [7,
8], suggesting a role of CAMK2N1 in tumorigenesis.
However, the role of CAMK2N1 in cancer has not been
investigated in more details. PI3K/AKT and MEK/ERK
signaling pathways have been shown to cooperate in
prostate cancer progression and the transition to castration
resistant disease [12]. Inhibition of these signaling
pathways acts combinatory to suppress the pathway
activation and inhibit tumor growth, cellular proliferation
and migration in prostate cancer [13]. Analyses of human
prostate tumor specimens suggest that PI3K/AKT and
MEK/ERK signaling pathways are frequently activated
by IGF-1, ErbB2, and VEGF in prostate tumors [13, 14,
15], via the phosphorylation, subsequent activation of NFκB, Bcl2 protein, and deactivation of p21 and Bad protein.
Increased activation of the PI3K-Akt-mTORC1 pathway
is a common aberration in prostate cancer [16]. IGF-1
acts as an important regulator of growth, survival, and
metastatic potential in a variety of malignancies and has
been shown to be involved in prostatic carcinogenesis and
CRPC [17]. IGF-1 also rapidly potentiates the activation
of Ca2+/CAMKII channel [18]. In this study, we observed
that CAMK2N1 suppressed the IGF-1, ErbB2, VEGF
expression and their downstream kinase-PI3K/AKT, and

CAMK2N1 suppresses IGF-1, ErbB2, VEGF,
downstream kinase-PI3K/AKT, MEK/ERK, and
HSP27-mediated signaling pathways in prostate
cancer cells.
To determine the mechanisms by which CAMK2N1
functions to inhibit prostate tumor growth, we performed
genome-wide gene expression analysis using human
12×135K gene expression array by comparing DU145
cells with or without CAMK2N1 overexpression (>
1.5-fold and p < 0.05). Pathway analysis conducted on
genes differentially regulated by CAMK2N1 revealed
several up-regulated signaling pathways, including
pathways that regulate cell-cycle arrest, apoptosis, and
DNA damage responses (Fig. 5A). This analysis also
identified several down-regulated pathways, including
pathways that control cell growth, cell migration, cell
adhesion, stress response, blood vessel development, and
cell communication. CAMK2N1 induced the expression
of genes encoding CDKN1A, BAX, BAD, GADD45A,
SFN, CAPNS1, CHEK1, CHEK2, CDKN2A, ANAPC11,
ANAPC5, SMAD2, SMAD3, CDC20, TGFB1, CASP4,
CASP7, ATF4, and EIF2A, while CAMK2N1 repressed
the expression of genes including IGF1, AKT1, BCL2,
VEGF, ERK1, IKBKB, NFKB1, STAT5B, CREB5,
ERBB2, BMP7, HSP27, CAMK2A, JAK3, PVRL1,
WNT3A, WNT9A, NFATC1, KLK2, and SPHK2 clusters
of genes (Fig. 5B). KEGG (Kyoto Encyclopedia of Genes
and Genomes) analysis identified an interconnected
network, including five major kinase pathways: IGF1,
VEGF, ERBB2, MEK/ERK, PI3K/AKT, which are
involved in cell growth, survival, migration or invasion,
and angiogenesis (Supplemental Figure 3A).
To validate the microarray data, we performed
Western blot and qRT-PCR analyses and focused on a
subset of genes that are either down-regulated (ErbB2,
AKT, MEK1, ERK1/2, Bcl-2) or up-regulated (p21, Bax).
Overexpression of CAM2KN1 in DU145 and PC3 cells
resulted in decreased ErbB2, MEK1, pMEK1T292, ERK1/2,
p-ERK1/2, AKT, pAKTser473, Bcl-2, NF-κB protein
expression and increased p21 and Bax protein expression
(Fig. 5C-D, Supplemental Figure 2C). Overexpression of
CAM2KN1 in DU145 tumor tissues resulted in decreased
ErbB2, AKT1, Bcl-2, NF-κB and AR mRNA levels and
increased p21, Bax mRNA levels (Figure 5E). Conversely,
knockdown of CAMK2N1 by shRNA in DU145 cells
led to an opposite effect on protein expression of these
genes (Supplemental Figure 1C). Taken together, these
data showed that CAMK2N1 regulates cell proliferation,
apoptosis and tumor growth in vivo, likely through the
functional interactions with these signaling molecules in
prostate cancer cells.
www.impactjournals.com/oncotarget
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Figure 5: CAMK2N1 suppresses IGF-1, ErbB2, VEGF, downstream kinase-PI3K/AKT, MEK/ERK and HSP27mediated signaling pathways in prostate cancer cells. (A-B) Microarray gene expression analysis was conducted in DU145 cells

stably overexpressing CAMK2N1 (>1.5-fold and p < 0.05). (A) Functional analysis of differentially expressed genes. Gene Ontology (GO)
Biological Process (BP) terms were ranked by score (score > 1.3). (B) CAMK2N1 induced and repressed clusters of genes that were chosen
from the pathways. (C-D) Expression levels of ErbB2, AKT, MEK1, ERK1/2, NFκβ, Bcl-2, BAX, and p21 were determined by Western
blot in DU145 cells with stably overexpressing CAMK2N1. Similar changes as to those found in the microarray analysis were observed.
Each figure represents three independent experiments. (E) DU145 tumors stably expressing CAMK2N1, and mRNA levels of ErbB2, Bcl-2,
NF-κβ, AKT1, AR, p21, and Bax were determined by qRT-PCR. CAMK2N1 decreased ErbB2, BCL-2, NF-κβ, AKT1, AR mRNA levels
and increased p21, Bax mRNA levels in DU145 tumor tissues. The data is shown as mean ± SEM for N=4 separate tumors for each group.
www.impactjournals.com/oncotarget
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MEK/ERK-mediated signaling pathways, which were
critical for cell proliferation and survival. Furthermore,
CAMK2N1 induced cell cycle regulatory kinases, p21, 143-3, Chk1, Chk2, possibly accounting for the G0/G1 arrest.
CAMK2N1 also induced apoptosis regulatory kinases
including Bax/Bcl2, Bad, caspase4, caspase7, explaining
how CAMK2N1 enhanced cell apoptosis. Collectively,
results from our study revealed the tumor suppressive role
of CAMK2N1 in prostate cancer.
In summary, we demonstrated that CAMK2N1
expression was reduced in prostate cancer. Increased
CAMK2N1 expression suppressed cell proliferation,
survival and tumor growth in vivo. These data suggested
that CAMK2N1 plays an important role in the progression
of prostate cancer. This study confirmed a value of
CAMK2N1 in predicting patient’s responsiveness, in
addition also established a potential of CAMK2N1 as
a therapeutic target. Re-expression of CAMK2N1 in
prostate cancer may provide clinical benefits to patients;
however, further studies are warranted to determine the
molecular mechanisms link between CAMK2N1 and
androgen receptor signaling in prostate cancer.

Cell Proliferation Assays

MATERIALS AND METHODS

Western Blot

2×103 stable cells were seeded in 96-well plate in
normal growth medium, and cell growth was measured
daily by MTT assays using 3-(4, 5-dimethylthiazol-2yl)-2, 5-diphenyltetrazolium bromide.

Cell Cycle and Apoptosis Analysis
Cell cycle parameters were determined by flow
cytometry. Stable cells were processed by standard
methods using propidium iodide staining of nuclear DNA.
Each sample was analyzed by flow cytometry with a
FACScan Flow Cytometer (Becton-Dickinson Biosciences,
Mansfield, MA) using a 488 nm laser. Histograms were
analyzed for cell cycle compartments using ModFit
version 2.0 (Verity Software House, Topsham, ME). A
minimum of 20,000 events were collected to maximize
statistical validity of the compartmental analysis. The PEAnnexin-V Apoptosis Detection Kit (BD Biosciences) was
used to detect apoptosis by flow cytometry [19].

Western blots were performed on DU145, PC3 and
LNCaP cells as indicated. Cells were pelleted and lysed
in buffer (50 mM HEPES, pH 7.2, 150 mM NaCl, 1
mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1% Tween 20)
supplemented with a protease inhibitor cocktail (Roche
Diagnostics, Mannheim, Germany). Antibodies used for
Western blots were: anti-CAMK2N1 (D-14) [7, 8] and
anti-AR (H-280) (Santa Cruz).

Cell culture, Plasmid construction, Reporter
genes, Expression vectors, and DNA transfection
Human prostate cancer DU145 and PC3 cells were
obtained from ATCC and maintained in DMEM medium
(Invitrogen) supplemented with 10% fetal bovine serum.
The CAMK2N1 human cDNA clone was purchased from
OriGene Technologies and subcloned into the EcoRI/
XhoI site of MSCV-IRES-GFP (Addgen) retroviral vector.
pGIPZ Vector, pGIPZ-shCAMK2N1(V3LHS-315689,
5’-TCAATAACAACCCGCTTGC-3’), were purchased
from Thermo Scientific. DU145 and PC3 cells infected
with MSCV-IRES-GFP, MSCV-CAMK2N1-IRES-GFP,
pGIPZ-Vector, pGIPZ-shCAMK2N1. GFP positive cells
were selected by FACS (Fluorescence Activated cell
sorter).

Microarray and Cluster Assays
DNA-free total RNA isolated from DU145 cells
expressing CAMK2N1 was used to probe Human
12×135K gene expression array (KangChen Bio-Tech).
RNA quality was determined by gel electrophoresis.
Probe synthesis and hybridization were performed in
NimbleGen Hybridization System. Analysis of the arrays
was performed using Agilent GeneSpring GX v11.5.1
software. Arrays were extracted and normalized using
NimbleScan v2.5 software, and the P-value of 0.05 was
applied as a statistical criteria for differentially expressed
genes. These genes were then grouped using hierarchical
clustering with “complete” agglomeration, and each
cluster was further analyzed based upon the known
function of the genes contained in the cluster. Expression
profiles were displayed using Treeview. Classification
and clustering for pathway level analysis were performed
by using gene sets ASSESS (Analysis of Sample Set
Enrichment Scores), available online. ASSESS provides
a measure of enrichment of each gene set in each sample.

Colony Formation Assays
Cells were plated in triplicates in 3 ml of 0.3%
agarose (sea plaque) in complete growth medium overlaid
on 0.5% agarose base, also in complete growth medium.
Two weeks post cell seeding, colonies were visualized
after staining with 0.04% crystal violet in methanol for
1-2 hrs. The colonies more than 50 µm in diameter were
counted using an Omnicon 3600 image analysis system.

www.impactjournals.com/oncotarget
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Gene set enrichment was dependent on a concordance
of at least two samples within the replicates that were
contrast between phenotypes [20, 21].

3

RNA Isolation and Quantitative Real-time PCR
(qRT-PCR) Assays
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Total RNA was isolated and reversely transcribed
to cDNA using TRIzol reagent (Invitrogen) and iScript
cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules,
CA), respectively, according to the manufacturer’s
instructions [22]. qRT-PCR was carried out in Bio-Rad
CFX96 Real-Time PCR Detection System with iQ SYBR
Green Supermix (Bio-Rad). Relative gene expression was
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Immunohistochemistry
Immunohistochemical analysis of human prostate
cancer was conducted using a polyclonal CAMK2N1
antibody [7, 8]. Human prostate cancer tissue arrays were
purchased from Biomax, US.

Nude Mice Study
2 × 106 DU145 cells and PC3 cells expressing
CAMK2N1 were implanted subcutaneously into
4-6-week-old athymic female nude mice purchased from
Beijing HFK Bio-Technology.co., LTD. Tumor growth
was measured using a digital caliper every 5 days for 4-5
weeks. Tumor weight was measured when mice were
sacrificed on day 32 after cell implantation.

10 Franklin RA1, McCubrey JA. The involvement of CaMKII in insulin induced cell proliferation. Cell Cycle. 2009;
8(13):1979.
11
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